Indian stock markets opened in the red on Tuesday amid escalating geopolitical tensions and rising crude oil prices, which sparked widespread selling by investors.

On July 14, 2026, markets turned cautious after a fresh escalation between the US and Iran in the Strait of Hormuz, with Washington saying it plans to impose shipping fees and neither side backing down. Brent crude jumped 9% in one session and briefly touched $86.60 a barrel, heightening worries about potential supply disruptions. India’s Sensex and Nifty fell 0.6% at the open, while the rupee weakened 33 paise to 95.95 per dollar.

The US Food and Drug Administration issued a warning letter dated July 10, 2026, to a clinical investigator linked to a bioequivalence study conducted at Alembic Pharma’s Vadodara facility. The letter followed an inspection conducted between March 3 and March 7, 2025, and cited issues related to the Informed Consent Form used in the study. Alembic said the observations are not related to data integrity and that the warning letter does not restrict facility operations or have a material financial impact at this stage. The company said the matter could slow the review of its abbreviated new drug application (ANDA) submissions to the USFDA, raising investor concerns about export risks.

Adani Enterprises raised Rs 15,000 crore through a qualified institutional placement, drawing strong participation from global and domestic institutions. The company said it will use the proceeds to fund expansion across copper smelting, airports, roads, data centres and green energy, alongside debt repayment and general corporate purposes. Morgan Stanley forecasts copper EBITDA of Rs 3,670 crore by FY30.

Gold prices rebounded in early Tuesday trading after slipping to a two-week low in the previous session, as investors positioned ahead of June U.S. CPI data. Traders have increased bets on a September Federal Reserve rate hike, with the implied probability rising to around 76% from 57% a week earlier. Spot gold was quoted at $4,013.93 an ounce, while U.S. gold futures added 0.4%. Oil prices climbed on escalating U.S.-Iran tensions, but rate expectations continued to dominate bullion sentiment.

HCL Technologies reported FY26 Q1 results, with net profit up 20% year on year to Rs 4,624 crore and revenue rising 14% to Rs 34,579 crore, while operating margin improved to 16.9%. The company kept its FY27 revenue growth guidance of 1-4% and EBIT margin guidance of 17.5-18.5%, and announced a Rs 3,500 crore investment in an AI data centre. Broker views diverged, with Citi cutting the stock to Sell, Nomura maintaining Buy and raising its target to Rs 1,290, while CLSA, Goldman Sachs and HSBC stayed broadly cautious and neutral.

TSMC is expected to report second-quarter net profit of $19.65 billion, up 59% year on year, setting a record high for a fifth straight quarter. Revenue is projected to rise 36% from a year earlier, also beating expectations. Analysts attribute the momentum to sustained AI infrastructure spending that is lifting demand for advanced manufacturing and CoWoS packaging. They also expect TSMC may raise its full-year revenue growth guidance, currently set at "above 30%", and update its capital spending outlook.

Mylan, now part of Viatris, plans to sell its entire Biocon stake via a block deal of up to 9.2 crore shares, representing 5.64% of the company, valued at up to Rs 3,481 crore. The deal is pitched at a floor price of Rs 378.50 per share, a 7.9% discount to the prior close. Citigroup Global Markets India and Jefferies India are joint bookrunners, and the sale comes ahead of Biocon’s Q1 results.